JAK2 mutations and clinical practice in myeloproliferative neoplasms.

Abstract excerpt

With the discovery in the last 3 years of novel Janus kinase 2 (JAK2) and thrombopoietin receptor (MPL) mutations, the pathogenetic understanding of and clinical practice for myeloproliferative neoplasms (MPNs) have entered a new era. Each one of these newly discovered mutations, including JAK2V617F, MPLW515L, and a JAK2 exon 12 mutation, has been shown to result in constitutive activation of JAK-STAT signaling...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to JAK2 gene
• Share to MPL gene
• Share to Janus Kinase 2